Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics

Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

December 12, 2024

Biotechnology

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.

Lupin to Acquire VISUfarma from GHO Capital

September 29, 2025

Pharmaceuticals

Lupin Limited, through its wholly owned subsidiary Nanomi B.V., has signed a definitive agreement to acquire VISUfarma B.V., a pan-European ophthalmology specialty pharmaceutical business. The deal is expected to close by the end of 2025, subject to customary closing conditions, and will expand Lupin’s specialty ophthalmology presence across major European markets.

Azurity Pharmaceuticals Acquires Covis Pharma

March 14, 2025

Pharmaceuticals

Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.

Cooper Consumer Health Acquires Viatris' Over-the-Counter Business

July 3, 2024

Pharmaceuticals

Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.

Santen Acquires Eyevance Pharmaceuticals for $225M

September 16, 2020

Pharmaceuticals

Santen Pharmaceutical Co., Ltd., through its U.S. subsidiary Santen Holdings U.S. Inc., acquired all outstanding shares of Eyevance Pharmaceuticals Holdings Inc. for $225 million in cash. The deal brings Eyevance’s topical ophthalmic product portfolio and U.S. commercial team into Santen’s global ophthalmology business; two development-stage assets (VISOVANQ and NEXAGON) were carved out and excluded from the purchase.

Vizgen Acquires Ultivue (Merger to Form Combined Spatial Biology Company)

October 9, 2024

Biotechnology

Vizgen and Ultivue have merged to create a single spatial biology company that combines Vizgen’s MERFISH single-cell spatial genomics platform with Ultivue’s InSituPlex assays and STARVUE proteomic/AI capabilities. Rob Carson (former CEO of Ultivue) will serve as President and CEO of the combined Vizgen, and the transaction was completed alongside Vizgen’s Series D financing backed by investors including ARCH Venture Partners, Northpond Ventures and Tao Capital Partners.